Race Oncology doses first patient in phase 1b/2 AML trial of FluCloZan

Race Oncology has dosed the first patient in the phase 1b/2 trial of its Zantrene (bisantrene dihydrochloride) in combination with Fludarabine and Clofarabine (FluCloZan) in ... Read More